Antitumoral activity of a xanthate compound. I. Cytotoxicity studies with neoplastic cell lines in vitro

Cancer Lett. 1989 Jul 15;46(2):143-7. doi: 10.1016/0304-3835(89)90022-0.


Xanthate derivatives were shown previously to display antitumor activity against transformed fibroblasts and lymphoma cells in combination with monocarboxylic acids [1]. Various malignant cell lines of human origin were treated in vitro to explore the range of antitumoral activity of the compounds. The combination of tricyclodecan-9-yl-xanthogenate (D 609) with undecanoic acid (C11) exerted dose dependent cytotoxic and antiproliferative effects on cell lines both from solid tumors (glioblastomas, colon-carcinomas) and hematological diseases (lymphomas, CML/BC). Additionally, the combination of D 609/C11 was able to kill both methotrexate- and adriamycin-resistant L 1210 and S 180 cells, indicating that there is no cross-resistance for these drugs and D 609/C11 in vitro.

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / pharmacology*
  • Bridged-Ring Compounds / administration & dosage
  • Drug Resistance
  • Fatty Acids / administration & dosage
  • Humans
  • Neoplasms / drug therapy*
  • Norbornanes
  • Thiocarbamates
  • Thiones / administration & dosage
  • Tumor Cells, Cultured


  • Bridged-Ring Compounds
  • Fatty Acids
  • Norbornanes
  • Thiocarbamates
  • Thiones
  • undecanoic acid
  • tricyclodecane-9-yl-xanthogenate